"According to the latest research study, the demand for Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets grow from $31.6 in 2023 and is estimated ...

The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Researchers determined a short duration of anticoagulation therapy could be beneficial in comparison to a longer course for primary treatment VTE.

The multibillion-dollar worldwide market for injectable antithrombotic drugs (including anticoagulants and antiplatelet agents) will continue to grow as minimally invasive surgical interventions ...

Anticoagulant dosing for the treatment of venous thromboembolic events has been historically extrapolated from clinical experiences in adults, and although the most experience has been with ...

Nonvalvular atrial fibrillation (AF) patients who take non-vitamin K oral anticoagulants (NOACs) along with certain other medications are at increased risk for major bleeding, and antithrombotic ...

The trial, which was published in The Lancet in 2013, demonstrated a significant reduction in bleeding risk with an oral anticoagulant and clopidogrel only — or “double therapy” — when ...

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of ...

View list of generic drugs that are classified under Anticoagulants / Antithrombotics along with ICD Code. Find related prescribing information and price details for each drug listed under it.

- RnRMarketResearch.com adds new market research reports "Antithrombotic / Anticoagulant Drugs: Technologies and Global Markets" to its store. This report provides an overview of the global market ...

Potential Biomarker, Drug Target ID’d for Adult Leukemia For patients with ischemic cerebrovascular disease taking antithrombotic drugs, the risk of bleeding varies for different medical ...

This is because the priority for pharmaceutical sponsors of trials of these agents is to study the drugs for regulatory approval in situations in which there are large numbers of patients for an ...